The shifting UK landscape surrounding mind-altering substances is increasingly nuanced, demanding careful assessment. While scientific inquiry into compounds like psilocybin and copyright continues to advance, and patient opportunity via private clinics is increasing, the regulatory framework remains unclear. This presents a challenging situation f